RNA Platform Polpharma recently launched a platform in Starogard Gdański for the development and manufacturing of RNA-based medicines, positioning it as a CDMO-ready hub. This creates opportunities for partnerships with biotech and pharma firms seeking scalable RNA production, development support, and regulatory services. Target clients include RNA therapeutics developers and oligonucleotide manufacturers.

Asia Expansion Polpharma's expansion of offices to India and other parts of Asia signals a strategic capability to supply APIs and perform contract manufacturing at scale. This supports multi-regional supply arrangements, faster market access, and diversified sourcing for global clients.

Regional Growth The Biofarm SA acquisition broadens Polpharma's footprint in Eastern Europe, enabling cross-border generics manufacturing, portfolio expansion, and regional distribution partnerships. This presents opportunities to co-market, co-develop, or supply generics across the region.

Leadership Momentum A leadership transition with a new President offers a window to establish strategic partnerships and long-term alliances, including licensing, distribution agreements, and co-development deals aligned with Polpharma's growth plan.

Market Leadership Polpharma's position as a leading generic producer in Central and Eastern Europe and Kazakhstan, along with established partnerships, provides a compelling platform for private-label deals, licensed generics, and scalable contract manufacturing across its markets.